Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 4, 2011, Pages 1064-1067

  Li, Xue Feng ^a   Zheng, You Lan ^a   Xiu, Mei Hong ^b   Chen, Da Chun ^b   Kosten, Thomas R ^c   Zhang, Xiang Yang ^b,c  

^a JILIN AGRICULTURAL UNIVERSITY   (China)

^b BEIJING HUILONGGUAN HOSPITAL   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antioxidant; First episode; Free radical; Psychopathology; Schizophrenia

Indexed keywords

ANTIOXIDANT;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DEPRESSION; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ADOLESCENT; ADULT; ANTIOXIDANTS; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EDUCATIONAL STATUS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OXIDATIVE STRESS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX CHARACTERISTICS; SMOKING; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 79956035550     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.03.001     Document Type: Article

References (40)

1. Akyol O., Herken H., Uz E., Fadillioglu E., Unal S., Sogut S., Ozyurt H., Savas H.A. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuro psychopharmacol Biol Psychiatry 2002, 26:995-1005.
2. Arvindakshan M., Ghate M., Ranjekar P.K., Evans D.R., Mahadik S.P. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 2003, 62:195-204.
3. Benzie I.F., Strain J.J. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 1996, 239:70-76.
4. Bitanihirwe B.K., Woo T.U. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 2011, 35(3):878-893.
5. Buckley P.F., Evans D. First-episode schizophrenia. A window of opportunity for optimizing care and outcomes. Postgrad Med Spec 2006, No: 5-19.
6. Buckman T.D., Kling A.S., Sutphin M.S., Steinberg A., Eiduson S. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. Psychiatry Res 1990, 31:1-14.
7. Chittiprol S., Venkatasubramanian G., Neelakantachar N., Babu S.V., Reddy N.A., Shetty K.T., Gangadhar B.N. Oxidative stress and neopterin abnormalities in schizophrenia: a longitudinal study. J Psychiatr Res 2010, 44(5):310-313.
8. Dietrich-Muszalska A., Kontek B. Lipid peroxidation in patients with schizophrenia. Psychiatry Clin Neurosci 2010, 64(5):469-475.
9. Do K.Q., Cabungcal J.H., Frank A., Steullet P., Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 2009, 19(2):220-230.
10. Gama C.S., Salvador M., Andreazza A.C., Kapczinski F., Silva Belmonte-de-Abreu P. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30(3):512-515.
11. Herken H., Uz E., Ozyurt H., Sogut S., Virit O., Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 2001, 6:66-73.
12. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-mediated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 2002, 58:1-10.
13. Lohr J.B. Oxygen radicals and neuropsychiatric illness, some speculations. Arch Gen Psychiatry 1991, 48:1097-1106.
14. Lohr J.B., Browning J.A. Free radical involvement in neuropsychiatric illnesses. Psychopharmacol Bull 1995, 31:159-165.
15. Lohr J.B., Kuczenski R., Niculescu A.B. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003, 17:47-62.
16. Mahadik S.P., Evans D.R. Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. Psychiatry Clin N Am 2003, 26:85-102.
17. Mahadik S.P., Mukherjee S., Correnti E.E., Scheffer R., Mahadik J. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry 1998, 43:674-679.
18. Mahadik S.P., Pillai A., Joshi S., Foster A. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int Rev Psychiatry 2006, 18(2):119-131.
19. McCreadie R.G., Macdonald E., Wiles D., Campbell G., Pateson J.R. The Nithsdale Schizophrenia Surveys XIV: plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia and in normal subjects. Br J Psychiatry 1995, 167:1-8.
20. Mukherjee S., Mahadik S.P., Scheefer R., Correnti E.E., Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophr Res 1996, 19:19-26.
21. Ng F., Berk M., Dean O., Bush A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008, 11(6):851-876.
22. Padurariu M., Ciobica A., Dobrin I., Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 2010, 479(3):317-320.
23. Pazvantoglu O., Selek S., Okay I.T., Sengul C., Karabekiroglu K., Dilbaz N., Erel O. Oxidative mechanisms in schizophrenia and their relationship with illness subtype and symptom profile. Psychiatry Clin Neurosci 2009, 63(5):693-700.
24. Raffa M., Mechri A., Othman L.B., Fendri C., Gaha L., Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(7):1178-1183.
25. Reddy R.D., Keshavan M., Yao J.K. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 2003, 62:205-212.
26. Selek S., Herken H., Bulut M., Ceylan M.F., Celik H., Savas H.A., Erel O. Oxidative imbalance in obsessive compulsive disorder patients: a total evaluation of oxidant-antioxidant status. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:487-491.
27. Smesny S., Kinder D., Willhardt I., Rosburg T., Lasch J., Berger G., Sauer H. Increased calcium-independent phospholipase A2 activity in first but not in multiepisode chronic schizophrenia. Biol Psychiatry 2005, 57(4):399-405.
28. Tsai G., Goff D.C., Chang R.W., Flood J., Baer L., Coyle J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998, 155:1207-1213.
29. Ustundag B., Atmaca M., Kirtas O., Selek S., Metin K., Tezcan E. Total antioxidant response in patients with schizophrenia. Psychiatry Clin Neurosci 2006, 60:458-464.
30. Virit O., Altindag A., Yumru M., Dalkilic A., Savas H.A., Selek S., Erel O., Herken H. A defect in the antioxidant defense system in schizophrenia. Neuropsychobiology 2009, 60(2):87-93.
31. Yao J.K., Keshavan M.S. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal 2010, Dec 2. [Epub ahead of print].
32. Yao J.K., Reddy R. Oxidative stress in schizophrenia: pathogenetic and therapeutic implications. Antioxid Redox Signal 2011, Jan 2. [Epub ahead of print].
33. Yao J.K., Reddy R., McElhinny L.G., van Kammen D.P. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 1998, 32(1):1-8.
34. Yao J.K., Reddy R., McElhinny L.G., van Kammen D.P. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J Psychiatr Res 1998, 32:385-391.
35. Yao J.K., Reddy R.D., van Kammen D.P. Abnormal age related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 2000, 97:137-151.
36. Yao J.K., Reddy R.D., van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001, 15:287-310.
37. Yao J.K., Dougherty G.G., Reddy R.D., Keshavan M.S., Montrose D.M., Matson W.R., McEvoy J., Kaddurah-Daouk R. Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia. PLoS ONE 2010 Mar 3, 5(3):e9508.
38. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Su J.M., Cao L.Y. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2001, 62:878-883.
39. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Res 2003, 117:85-88.
40. Zhang X.Y., Zhou D.F., Cao L.Y., Chen D.C., Zhu F.Y., Wu G.Y. Blood superoxide dismutase level in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res 2003, 62:245-250.